Cargando…

Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action

There is a desperate need for novel and efficacious chemotherapeutic strategies for human brain cancers. There are abundant molecular alterations along the p53 and MDM2 pathways in human glioma, which play critical roles in drug resistance. The present study was designed to evaluate the in vitro and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Punganuru, Surendra R., Arutla, Viswanath, Zhao, Wei, Rajaei, Mehrdad, Deokar, Hemantkumar, Zhang, Ruiwen, Buolamwini, John K., Srivenugopal, Kalkunte S., Wang, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408354/ https://www.ncbi.nlm.nih.gov/pubmed/32630235 http://dx.doi.org/10.3390/cells9071592

Ejemplares similares

Characterization of a highly specific NQO1-activated near-infrared fluorescent probe and its application for in vivo tumor imaging
por: Punganuru, Surendra Reddy, et al.
Publicado: (2019)

Cancer-Specific Biomarker hNQO1-Activatable Fluorescent Probe for Imaging Cancer Cells In Vitro and In Vivo
por: Punganuru, Surendra Reddy, et al.
Publicado: (2018)

Targeting MDM2 for Neuroblastoma Therapy: In Vitro and In Vivo Anticancer Activity and Mechanism of Action
por: Wang, Wei, et al.
Publicado: (2020)

Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies
por: Madala, Hanumantha Rao, et al.
Publicado: (2018)

Conception, synthesis, and characterization of a rofecoxib-combretastatin hybrid drug with potent cyclooxygenase-2 (COX-2) inhibiting and microtubule disrupting activities in colon cancer cell culture and xenograft models
por: Punganuru, Surendra R., et al.
Publicado: (2018)

Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy
por: Qin, Jiang-Jiang, et al.
Publicado: (2018)

Brain- and brain tumor-penetrating disulfiram nanoparticles: Sequence of cytotoxic events and efficacy in human glioma cell lines and intracranial xenografts
por: Madala, Hanumantha Rao, et al.
Publicado: (2017)

Genomic Space of MGMT in Human Glioma Revisited: Novel Motifs, Regulatory RNAs, NRF1, 2, and CTCF Involvement in Gene Expression
por: Ibrahim Al-Obaide, Mohammed A., et al.
Publicado: (2021)

The MDM2-p53 pathway revisited
por: Nag, Subhasree, et al.
Publicado: (2013)

S-phase Specific Downregulation of Human O(6)-Methylguanine DNA Methyltransferase (MGMT) and its Serendipitous Interactions with PCNA and p21(cip1) Proteins in Glioma Cells
por: Mostofa, AGM, et al.
Publicado: (2018)

The Process and Regulatory Components of Inflammation in Brain Oncogenesis
por: Mostofa, A.G.M., et al.
Publicado: (2017)

A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance
por: Wang, Wei, et al.
Publicado: (2019)

Two Birds with One Stone: NFAT1-MDM2 Dual Inhibitors for Cancer Therapy †
por: Wang, Wei, et al.
Publicado: (2020)

Synthesis, Biological Evaluation and Modeling Studies of New Pyrido[3,4-b]indole Derivatives as Broad-Spectrum Potent Anticancer Agents
por: Patil, Shivaputra A, et al.
Publicado: (2017)

New insights into estrogenic regulation of O(6)-methylguanine DNA-methyltransferase (MGMT) in human breast cancer cells: Co-degradation of ER-α and MGMT proteins by fulvestrant or O(6)-benzylguanine indicates fresh avenues for therapy
por: Paranjpe, Ameya, et al.
Publicado: (2016)

Oral nano-delivery of anticancer ginsenoside 25-OCH(3)-PPD, a natural inhibitor of the MDM2 oncogene: Nanoparticle preparation, characterization, in vitro and in vivo anti-prostate cancer activity, and mechanisms of action
por: Voruganti, Sukesh, et al.
Publicado: (2015)

Transcriptional Pausing and Activation at Exons-1 and -2, Respectively, Mediate the MGMT Gene Expression in Human Glioblastoma Cells
por: Al-Obaide, Mohammed A. Ibrahim, et al.
Publicado: (2021)

Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation
por: Qin, Jiang-Jiang, et al.
Publicado: (2014)

Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA
por: Qin, Jiang-Jiang, et al.
Publicado: (2015)

MDM4 Isoform Expression in Melanoma Supports an Oncogenic Role for MDM4-A
por: Alatawi, Abdullah, et al.
Publicado: (2021)

Ginsenosides as Anticancer Agents: In vitro and in vivo Activities, Structure–Activity Relationships, and Molecular Mechanisms of Action
por: Nag, Subhasree Ashok, et al.
Publicado: (2012)

Augmented antitumor activity of 5‐fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells
por: Imanishi, Mamiko, et al.
Publicado: (2019)

MDM2 Oncogene Copy Number Alterations in Chronic Lymphocytic Leukemia
por: Sookaromdee, Pathum, et al.
Publicado: (2019)

Proteasome activator PA28γ regulates p53 by enhancing its MDM2-mediated degradation
por: Zhang, Zhuo, et al.
Publicado: (2008)

Antitumor effects of Dasatinib on laryngeal squamous cell carcinoma in vivo and in vitro
por: Song, Yan, et al.
Publicado: (2013)

Identification of lineariifolianoid A as a novel dual NFAT1 and MDM2 inhibitor for human cancer therapy
por: Qin, Jiang-Jiang, et al.
Publicado: (2016)

Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy
por: Qin, Jiang-Jiang, et al.
Publicado: (2016)

The In Vivo Role of the RP-Mdm2-p53 Pathway in Signaling Oncogenic Stress Induced by pRb Inactivation and Ras Overexpression
por: Pan, Wenqi, et al.
Publicado: (2011)

Inhibition of Mdmx (Mdm4) in vivo induces anti-obesity effects
por: Kon, Ning, et al.
Publicado: (2018)

E2F1-Dependent Oncogenic Addiction of Melanoma Cells to MDM2
por: Verhaegen, Monique, et al.
Publicado: (2011)

Investigation of MDM2 Oncogene Copy Number Alterations in Cases of Chronic Lymphocytic Leukemia
por: Darbaş, Şule, et al.
Publicado: (2019)

Serum Response Factor (SRF) Drives the Transcriptional Upregulation of the MDM4 Oncogene in HCC
por: Pellegrino, Rossella, et al.
Publicado: (2021)

Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen
por: Qin, Jiang-Jiang, et al.
Publicado: (2017)

JKA97, a Novel Benzylidene Analog of Harmine, Exerts Anti-Cancer Effects by Inducing G1 Arrest, Apoptosis, and p53-Independent Up-Regulation of p21
por: Yang, Xinyi, et al.
Publicado: (2012)

Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine
por: Qin, Jiang-Jiang, et al.
Publicado: (2018)

Experimental Therapy of Ovarian Cancer with Synthetic Makaluvamine Analog: In Vitro and In Vivo Anticancer Activity and Molecular Mechanisms of Action
por: Chen, Tao, et al.
Publicado: (2011)

In Vivo and in vitro antitumor activity of tomatine in hepatocellular carcinoma
por: Echeverría, Cesar, et al.
Publicado: (2022)

Antitumor Effects of Self-Assembling Peptide-Emodin in situ Hydrogels in vitro and in vivo
por: Wei, Weipeng, et al.
Publicado: (2021)

MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways
por: Saiki, Anne Y., et al.
Publicado: (2014)

Antitumor activity of dichloroacetate on C6 glioma cell: in vitro and in vivo evaluation
por: Duan, Yu, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_mpopg168pnjff4j8u18rsi5q5p